FDA approves new HIV drug from Johnson & Johnson
The Food and Drug Administration says it approved a new HIV drug from Johnson & Johnson for patients who have not been treated with other medications for the virus.
The once-a-day pill Edurant works by blocking the virus from reproducing. It is designed to be used with other drugs that reduce levels of HIV in the blood.
FDA officials say the approval provides an additional option to HIV patients, who respond differently to various medications.
The FDA approved the drug based on a study showing it was as effective as Sustiva, an older HIV drug already on the market.